Related Experiment Videos
Therapeutic options for patients returning to sexual activity
1Department of Family Medicine, University of North Carolina at Chapel Hill, Manning Dr, Chapel Hill, NC 27599-7595, USA. margaret_nusbaum@med.unc.edu
The Journal of the American Osteopathic Association
|April 16, 2004
Summary
Phosphodiesterase type 5 (PDE5) inhibitors like tadalafil and vardenafil show effectiveness comparable to sildenafil for erectile dysfunction (ED). Longer-acting PDE5 inhibitors offer greater flexibility and reduce performance pressure for men with ED.
Area of Science:
- Pharmacology
- Urology
- Men's Health
Background:
- No direct comparative studies exist for phosphodiesterase type 5 (PDE5) inhibitors.
- Noncomparative data suggest tadalafil and vardenafil hydrochloride are effective for erectile dysfunction (ED).
Purpose of the Study:
- To evaluate the comparative effectiveness of PDE5 inhibitors.
- To highlight the benefits of longer-acting PDE5 inhibitors in ED management.
Main Methods:
- Review of noncomparative studies on PDE5 inhibitors.
- Analysis of treatment outcomes for erectile dysfunction.
Main Results:
- Tadalafil and vardenafil appear as effective as sildenafil citrate in improving erectile function.
- PDE5 inhibitors facilitate natural sexual response and improve intercourse success rates.
- Longer-acting agents like tadalafil offer increased flexibility and reduce the need for strict timing.
Conclusions:
- PDE5 inhibitors are effective options for managing erectile dysfunction.
- Tadalafil's longer duration of action provides enhanced flexibility for patients and partners.
- These medications can help restore sexual lifestyles and reduce performance anxiety in men with ED.